PATENT CLAIM ANALYSIS

Application Number: 15904086
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["424", "489000"]

Abstract:
A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.

Claim (Index 19):
The method of  claim 16 , wherein the patient suffering from bipolar disorder is being treated with quetiapine fumarate as an adjunct to lithium or divalproex.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.5
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15627087', '13518981', '14216342', '13581496', '14525836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6990097770099745
- 35 USC 102 Novelty (BERT): 0.5884180557505994
- Combined Prediction Score: 0.6879506048840369
- Mean Citation Score: 286.621392
- Max Citation Score: 533.6253
- Similarity Product: 380.5960852006138

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test